The Weil Institute of Critical Care Medicine (WICCM) obtains a number of significant patents from its groundbreaking, and clinically corroborated, research on the connection between tissue hypoperfusion and CO2 levels in bodily mucosal tissue.
ExoStat’s predecessor, Optical Sensors, Inc., enters a patent agreement with WICCM and develops the first and only cleared-to-market technology to measure pCO2 in sublingual tissue.
ExoStat is spun off from its parent company in order to focus efforts and resources on developing an improved version of the technology.
ExoStat enters into a long-term patent licensing and technology agreement with SensoCure, AS, a Norwegian sensor development company that holds several key sensor technology patents
Technology breakthroughs have been achieved and ExoStat is in the final stages of product development.
The new MicroTrendTM System features an 8 hour hands free monitoring system that provides currently unavailable data identifying tissue perfusion.